Prevention & lipidsMeta-analysis
Association of apolipoprotein levels with all-cause and cardiovascular mortality
- Systematic review and meta-analysis
Authors' conclusion
In this study, we found that Apo levels were linked to cardiovascular and all-cause mortality.
Study context
- Population
- Individuals in studies of apolipoprotein levels and mortality (English language, to 28 November 2022)
- Participants
- 152,854 individuals · 23 studies
- Comparison
- Apolipoprotein levels and all-cause and CV mortality
- Outcome
- All-cause and CV mortality
Pooled result
As reported in the abstract
Odds ratio (95% CI)
ApoA levelCV mortality
0.69(0.52–0.93)
Increased ApoB/A1 ratioCV mortality
2.13(1.48–3.07)
Increased ApoB/A1 ratioall-cause mortality
2.05(1.52–2.77)
ApoB levelCV mortality; not statistically significant
1.12(0.85–1.47)
Further pooled results
Sensitivity analysis, ApoA1 and all-cause mortality
| Comparison | OR (95% CI) | |
|---|---|---|
| ApoA1 · excluding Nomikos | 0.77 (0.65–0.92) | |
| ApoA1 · excluding Zeng | 0.77 (0.65–0.91) | |
| 0.512Odds ratio (log scale) |
Sensitivity analysis, ApoA1 and all-cause mortality
- Results almost robust apart from these exclusions
Original publication
Association of apolipoprotein levels with all-cause and cardiovascular mortality. Eur J Prev Cardiol. Published 28 February 2024. doi:10.1093/eurjpc/zwae080
Summarised from the published abstract; every number is checked against it